CONSENT II: Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

Trial Profile

CONSENT II: Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Coversin (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Acronyms CONSENTII
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 09 Feb 2018 Status changed from planning to not yet recruiting.
    • 12 Sep 2016 According to an Akari Therapeutics media release, the US FDA granted an orphan drug designation to coversin for the treatment of PNH.
    • 13 Jul 2016 According to an Akari Therapeutics media release, the company received an approval from UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase 2 trial of Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top